Skip to main content
Press Release

Calidi Biotherapeutics Announces Appointment of Alfonso “Chito” Zulueta, Former President of International for Eli Lilly, to Its Board of Directors

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a Nevada corporation (“Calidi”), is a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, announced today the appointment of Alfonso "Chito" Zulueta to its Board of Directors, effective February 7, 2022. Zulueta…
Calidi Biotherapeutics
February 4, 2022
Press Release

Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

-Total gross proceeds from transaction expected to be approximately $117 million prior to redemptions, combining $25 million PIPE and up to $92 million held in Edoc trust account- -Anticipated cash resources will fund Calidi’s NeuroNova and SuperNova development programs through multiple clinical milestones- -Business combination…
Calidi Biotherapeutics
February 2, 2022
Press Release

Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today that its physician advisor, Maciej S. Lesniak, MD, Department Chair of Neurological Surgery, Feinberg School of Medicine, Northwestern University, will present at the…
Calidi Biotherapeutics
November 5, 2021
Press Release

Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company with novel allogeneic stem cell platforms for delivery of oncolytic viruses, together with the University of Chicago and City of Hope, a world renowned NCI-Designated Comprehensive Cancer Center, based in Duarte, California, have entered into…
Calidi Biotherapeutics
August 16, 2021
Press Release

Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today that it has executed a license agreement with Northwestern University for the exclusive commercialization rights to the IND and data generated from Northwestern’s…
Press Release

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its partnership with GenScript ProBio, the biopharmaceutical contract research organization (CRO) and contract development and manufacturing organization (CDMO) segment…
Press Release

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that it has been granted a new patent from the European Patent Office (EPO). European Patent Number 3209382, “Combination Immunotherapy…
Calidi Biotherapeutics
December 1, 2020